Envista Holdings Corp (NVST) is a Healthcare stock trading at $26.95 (as of 2026-08-20), with a market capitalization of $4.33B and a trailing P/E of 42.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Envista Holdings makes and markets dental products used to diagnose, treat, and prevent dental conditions, and it earns money by selling dental implant systems, dental prosthetics, and related equipment and consumables.
The profit engine is the mix of sales across its two dental product businesses, Specialty Products & Technologies and Equipment & Consumables.
| Specialty | $0.5B |
| Equipment | $0.3B |
Business quality (Mixed): In the latest reported period (2026-04-03), Envista reported 55.3% gross margin and 8.9% operating margin, showing profitability after operating costs, alongside a revenue split between its Specialty and Equipment businesses.
Valuation: At 66× earnings, NVST trades 103% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $26.95 |
| Market Cap | $4.33B |
| P/E Ratio | 42.9 |
| EV / EBITDA | 12.3 |
| Price / Book | 1.41 |
| Price / Sales | 1.54 |
| FCF Yield | 4.5% |
| DCF Value (model) | $5.53 |
| DCF Upside vs Price | -79.5% |
| Revenue (TTM) | $2.72B |
| Net Margin | 1.7% |
| Return on Equity | 3.1% |
| Debt / Equity | 0.47 |
| Current Ratio | 2.43 |
| Revenue Growth (YoY) | 8.3% |
| EPS Growth (YoY) | -104.3% |
| FCF Growth (YoY) | -23.9% |
| Altman Z-Score | 1.77 (distress) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 42.9 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | 98.8% |
| vs Industry | 30.6% |
| Top Institutional Holder | BlackRock, Inc. ($452.93M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 1 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Paul A. Keel |
| Employees | 12,300 |
| Country | US |
| IPO Date | 2019-09-18 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.